These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20410840)

  • 1. Angioedema occurring in pediatric patients with Crohn disease treated with adalimumab.
    Adamiak T; Stephens M; Werlin SL
    J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):223-5. PubMed ID: 20410840
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease.
    Zella GC; Weinblatt ME; Winter HS
    J Pediatr Gastroenterol Nutr; 2009 Sep; 49(3):355-8. PubMed ID: 19516196
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 4. Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
    Sànchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N; Ruiz-Villaverde R
    Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S128. PubMed ID: 17067448
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease.
    Jordan N; Waghmare A; Abi-Ghanem AS; Moon A; Salvatore CM
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):294-6. PubMed ID: 21694635
    [No Abstract]   [Full Text] [Related]  

  • 7. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 8. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy.
    Manz M; Beglinger C; Vavricka SR
    Gut; 2009 Jan; 58(1):149. PubMed ID: 19091839
    [No Abstract]   [Full Text] [Related]  

  • 9. Transient menorrhagia without adalimumab discontinuation in a patient with Crohn's disease.
    Katsanos KH; Tsianos VE; Tsianos EV
    J Crohns Colitis; 2010 Sep; 4(3):348. PubMed ID: 21122527
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
    Gupta A; Pendyala P; Arora P; Sitrin MD
    J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
    Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults.
    Colombel JF
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):163-76. PubMed ID: 19072351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aortic thrombosis in young women with Crohn's disease receiving adalimumab: report of two cases.
    Leblanc S; Lloret Linares C; Cacheux W; Mouthon L; Chaussade S
    Inflamm Bowel Dis; 2011 Mar; 17(3):862-3. PubMed ID: 20629181
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute lymphoid leukemia in a Crohn's disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids.
    Cesarini M; Vernia P; Angelucci E
    Inflamm Bowel Dis; 2010 Mar; 16(3):371-2. PubMed ID: 19637388
    [No Abstract]   [Full Text] [Related]  

  • 15. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal Crohn's disease successfully treated with adalimumab.
    Tursi A
    Endoscopy; 2011; 43 Suppl 2 UCTN():E22. PubMed ID: 21271523
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
    Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.
    Vannucchi V; Grazzini M; Pieralli F; Giannotta M; Biagioni C; Nozzoli C
    J Gastrointestin Liver Dis; 2011 Jun; 20(2):201-3. PubMed ID: 21725519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch.
    Shen B; Remzi FH; Lavery IC; Lopez R; Queener E; Shen L; Goldblum J; Fazio VW
    Aliment Pharmacol Ther; 2009 Mar; 29(5):519-26. PubMed ID: 19183338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience.
    Oussalah A; Babouri A; Chevaux JB; Stancu L; Trouilloud I; Bensenane M; Boucekkine T; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Feb; 29(4):416-23. PubMed ID: 19035976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.